Copertina

Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Bochra Zareini, Katrine Kold Sørensen, Ulrik Pedersen‐Bjergaard, Emil Loldrup Fosbøl, Lars Køber, Christian Torp‐Pedersen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Journal of Diabetes
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes
di: Kathrine Kold Sørensen, et al.
Pubblicazione: (2026)

Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
di: Estela Lajthia
Pubblicazione: (2019)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
di: Richard J. MacIsaac, et al.
Pubblicazione: (2024)

An efficient stability criterion for process control systems based on numerical computation of matrix square root with predefined accuracy
di: Hooman Fatoorehchi, et al.
Pubblicazione: (2026)

Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
di: Natalia Andrea Rojas-Henao
Pubblicazione: (2018)

Association between the body mass index and risk of cardiovascular events in sodium‐glucose cotransporter 2 inhibitor users compared with dipeptidyl‐peptidase 4 inhibitor users: A nationwide cohort study in Korea
di: Hwa Yeon Ko, et al.
Pubblicazione: (2025)

Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
di: Hideaki Hashimoto, et al.
Pubblicazione: (2024)

Rapid screening and identification of novel dipeptidyl peptidase IV inhibitory peptides from buffalo milk
di: Qianqian Zheng, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
di: Yu Mi Kang, et al.
Pubblicazione: (2025)

Clinical progress note: Glucagon‐like peptide‐1 receptor agonists and hospitalized patients
di: Anjali Ravee, et al.
Pubblicazione: (2024)

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
di: Dario Giugliano, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists and hair loss: An emerging clinical concern
di: Jose María Camino‐Salvador, et al.
Pubblicazione: (2025)

Increased risk of hypereosinophilia following initiation of glucagon‐like peptide 1 receptor agonist: A symmetry analysis using the Danish health registries
di: Martin Torp Rahbek, et al.
Pubblicazione: (2024)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
di: Andy Bowe, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists and upper endoscopy: a real‐world experience
di: Pichamol Jirapinyo, et al.
Pubblicazione: (2025)

Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from Ziziphus jujuba peptide KALVAP
di: Huan Wen, et al.
Pubblicazione: (2025)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
di: Robert L. Dubin, et al.
Pubblicazione: (2024)

Glucagon‐like peptide‐1 receptor agonists in pediatric metabolic dysfunction‐associated steatotic liver disease
di: Andrea M. Tou, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
di: Giovanni Antonio Silverii, et al.
Pubblicazione: (2024)

Exploring dipeptidyl peptidase‐IV inhibitory peptides from Tartary Buckwheat protein: A study of hydrolysis, fractionation, and molecular interactions
di: Weijing Wu, et al.
Pubblicazione: (2024)

Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review
di: David Russell‐Jones, et al.
Pubblicazione: (2024)

Comparative efficacy and safety of dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes mellitus: A network meta‐analysis
di: Gongquan Wang, et al.
Pubblicazione: (2024)

Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
di: Hsiao‐Ling Chen, et al.
Pubblicazione: (2024)

Poor socioeconomic outcomes: Completion of the final examination after lower secondary education mitigates risks associated with gestational age
di: Rikke Wiingreen, et al.
Pubblicazione: (2024)

Correction to: Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
Pubblicazione: (2024)

Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
di: Andrea Saglietto, et al.
Pubblicazione: (2024)

Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
di: Tsung‐Hua Shen, et al.
Pubblicazione: (2024)

Serum interleukin‐10 level is increased and correlated positively with disease severity in patients with dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid
di: Shoya Suzuki, et al.
Pubblicazione: (2024)

Biotransformation and disposition characteristics of HSK7653 , a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes
di: Yi‐cong Bian, et al.
Pubblicazione: (2024)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
di: Claire H. Parker, et al.
Pubblicazione: (2025)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
di: Lucas A. Mavromatis, et al.
Pubblicazione: (2025)

Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
di: Hui‐Lin Sung, et al.
Pubblicazione: (2024)

A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers
di: Jibran Ahmed, et al.
Pubblicazione: (2025)

Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability
di: Johnny T. K. Cheung, et al.
Pubblicazione: (2024)

Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?
di: Grace Meulman, et al.
Pubblicazione: (2026)

A cohort description and comparison of four European national diabetes registries for the REDDIE project
di: Jonah J. C. Thomas, et al.
Pubblicazione: (2025)

Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
di: Pedro H. Reis‐Barbosa, et al.
Pubblicazione: (2024)

Glucagon‐like peptide‐1 receptor agonists in alcohol use disorder: Multi‐system effects, early clinical promise and uncertain long‐term use
di: Carolina L. Haass‐Koffler
Pubblicazione: (2026)

Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies
di: Ronald M. Goldenberg, et al.
Pubblicazione: (2025)

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
di: Mitsuhiro Shikamura, et al.
Pubblicazione: (2024)